123 related articles for article (PubMed ID: 1997112)
1. Phase II trial of trimelamol in refractory ovarian cancer.
Judson IR; Calvert AH; Gore ME; Balmanno K; Gumbrell LA; Perren T; Wiltshaw E
Br J Cancer; 1991 Feb; 63(2):311-3. PubMed ID: 1997112
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
4. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
Boven E; Nauta MM; Schlüper HM; Erkelens CA; Pinedo HM
Cancer Chemother Pharmacol; 1986; 18(2):124-8. PubMed ID: 3098444
[TBL] [Abstract][Full Text] [Related]
5. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
[TBL] [Abstract][Full Text] [Related]
6. Hexamethylmelamine (NSC-13875) in the treatment of advanced cancer.
Wampler GL; Mellette SJ; Kuperminc M; Regelson W
Cancer Chemother Rep; 1972 Aug; 56(4):505-14. PubMed ID: 5081594
[No Abstract] [Full Text] [Related]
7. A phase II trial of gallium nitrate (NSC #15200) in previously treated ovarian carcinoma. A Gynecologic Oncology Group Study.
Malfetano JH; Blessing JA; Adelson MD
Am J Clin Oncol; 1991 Aug; 14(4):349-51. PubMed ID: 1862766
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE
Clin Cancer Res; 1996 Oct; 2(10):1699-704. PubMed ID: 9816119
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary. A Gynecologic Oncology Group study.
Arseneau JC; Bundy B; Homesley H; Beecham J
Invest New Drugs; 1983; 1(2):185-8. PubMed ID: 6236163
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.
Miglietta L; Amoroso D; Bruzzone M; Granetto C; Catsafados E; Mammoliti S; Guarneri D; Pedulla F; Foglia G; Ragni N; Martini MC; Brema F; Addamo G; Moraglio L; Pastorino G; Boccardo F
Oncology; 1997; 54(2):102-7. PubMed ID: 9075779
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
Spannuth WA; Leath CA; Huh WK; Barnes MN; Davidson SA; Kilgore LC; Partridge EE; Austin JM; Alvarez RD
Gynecol Oncol; 2007 Mar; 104(3):591-5. PubMed ID: 17045635
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.
Hoffman MA; Blessing JA; Morgan M
Gynecol Oncol; 2000 Dec; 79(3):463-5. PubMed ID: 11104620
[TBL] [Abstract][Full Text] [Related]
15. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Hochster H; Plimack ER; Runowicz CD; Speyer J; Wallach RC; Sorich J; Mandeli J; Wadler S; Wright J; Muggia FM
J Clin Oncol; 2004 Jan; 22(1):120-6. PubMed ID: 14701774
[TBL] [Abstract][Full Text] [Related]
16. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
17. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Covens A; Blessing J; Bender D; Mannel R; Morgan M;
Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K
Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
Eisenhauer EA; Swenerton KD; Sturgeon JF; Fine S; O'Reilly SE
Cancer Treat Rep; 1986 Oct; 70(10):1195-8. PubMed ID: 3530446
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer.
Markman M; Lichtman SM; Homesley H; Kennedy A; Webster K; Ernst S; Omura G; Belinson J
Gynecol Oncol; 1998 Jul; 70(1):123-6. PubMed ID: 9698488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
